Clinical Trials

Urological Tumors

Recruitment stopped
Ongoing Recruitment

Prostata Carcinoma

NCT-PMO-1603 TOP-ART

(second-line, BRCAness)
Title:A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Indication:Krebs mit DNA-Reparatur-Defizite
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
[barbara.stoehr@nct-heidelberg.de]
Investigator: Prof. Dr. Stefan Fröhling (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03127215
EudraCT: 2017-001755-31 (siehe EU klinisches Studienregister)

Probase

(diagnostisch, Früherkennung, Screening)
Title:Risk-adapted prostate cancer early detection study based on a “baseline” PSA value in young men – a prospective multicenter randomized trial
Indication:Diagnosis of prostate cancer
Type of study:Phase N/A
Contact: Jutta von Kraewel (Kontaktperson)
[Jutta.Kraewel@med.uni-heidelberg.de]
Investigator: Prof. Dr. Markus Hohenfellner (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Retest- Studie

(diagnostisch, Früherkennung, Screening)
Title:Wiederholung kontrastmittelfreier MRT Sequenzen am selben Tag nach erfolgter vollständiger Prostata MRT zur Bestimmung radiomischer Parameterstabilität
Indication:Prostatakarzinom
Type of study:Phase N/A
Contact: Radiologie, DKFZ (E10) (Kontaktperson)
[-]
Investigator: PD Dr. med. David Bonekamp (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

68-Ga-PMSA-PET_CT und PET_MRT

(diagnostisch, Screening)
Title:Vergleich der diagnostischen Genauigkeit von 68Ga-PSMA-PET/CT und -PET/MRT beim präoperativen Staging bzw. Re-Staging von Patienten mit gesichertem oder klinischem Verdacht auf ein Prostatakarzinom.
Indication:Prostatakarzinom
Type of study:Phase N/A
Contact: Dr. med. Matthias C. Roethke (Kontaktperson)
[m.roethke@dkfz.de]
Investigator: Dr. med. Matthias C. Roethke (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

PROTEST

(radiologisch)
Title:PR0statakarzinom: TESTosteronspiegel nach Bestrahlung
Indication:Prostatakarzinom
Type of study:Phase N/A
Contact: Dr. med. Stefan Körber (Kontaktperson)
[stefan.körber@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Klaus Herfarth (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

LAP-01

(supportive care trial, chirurgisch)
Title:Randomisierte, multizentrische Studie zum Vergleich der roboterassistierten und der konventionellen laparoskopischen radikalen Prostatektomie
Indication:prostate cancer
Type of study:Phase N/A
Contact: Helga Gutzler (Kontaktperson)
[helga.gutzler@med.uni-heidelberg.de]
Investigator: Dr.med Joanne Nyarangi-Dix (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Bocciardi

Title:Retziussparende radikale Prostatektomie (Bocciardi Technik) . Evaluation der Bocciardi Technik für die daVinci assistierte Prostatektomie.
Indication:Prostatakrebs
Type of study:Phase N/A
Contact: Helga Gutzler (Study Nurse)
[helga.gutzler@med.uni-heidelberg.de]
Investigator: Dr.med Joanne Nyarangi-Dix (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

CA 209-9KD [Rekrutierung nach Rücksprache]

Title:A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
Indication:Metastasiertes Prostatakarzinom
Type of study:Phase II
Contact: Margit Peters-Hornig (Study Nurse)
[margit.peters-hornig@med.uni-heidelberg.de]
Investigator: Prof. Dr. Carsten Grüllich (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03338790
EudraCT: 2017-001626-17 (siehe EU klinisches Studienregister)

OPTIMISE-1

Title:Oncologic Therapy Support Via Means of a Dedicated Mobile App - a Prospective Feasibility Evaluation
Indication:Strahlentherapie mit potenziell kurativer Absicht eines primär thorakalen oder Beckenziels.
Type of study:Phase N/A
Contact: Dr. med. Rami El-Shafie (Kontaktperson)
[Rami.Elshafie@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Jürgen Debus (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03168048
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

PAROS

Title:Prostatalogenbestrahlung mit alternativen radioonkologischen Ansätzen.
Indication:Prostatakarzinom
Type of study:Phase III
Contact: Dr. med. Stefan Körber (Kontaktperson)
[Stefan.Koerber@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Klaus Herfarth (Prüfer)
Trial Register: Die Studie ist beim "DRKS - Deutsches Register Klinischer Studien" registriert. Siehe DRKS00015231
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

TRITON 2

Title:A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
Indication:Metastatic castration-resistant prostate cancer
Type of study:Phase II
Contact: Margit Peters-Hornig (Study Nurse)
[margit.peters-hornig@med.uni-heidelberg.de]
Investigator: Prof. Dr. Carsten Grüllich (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02952534
EudraCT: 2016-003162-13 (siehe EU klinisches Studienregister)

Renal Carcinoma

NCT-PMO-1603 TOP-ART

(second-line, BRCAness)
Title:A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Indication:Krebs mit DNA-Reparatur-Defizite
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
[barbara.stoehr@nct-heidelberg.de]
Investigator: Prof. Dr. Stefan Fröhling (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03127215
EudraCT: 2017-001755-31 (siehe EU klinisches Studienregister)

CANTATA/CX-839-008

Title:A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Indication:Patienten mit fortgeschrittenem oder metastasiertem Nierenzellkarzinom
Type of study:Phase II
Contact: Margit Peters-Hornig (Study Nurse)
[margit.peters-hornig@med.uni-heidelberg.de]
Investigator: Stefanie Zschäbitz (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03428217
EudraCT: 2018-000363-91 (siehe EU klinisches Studienregister)

SUNNIFORECAST

Title:A Phase 2, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated and Advanced (Unresectable or Metastatic) Non-clear Cell Renal Cell Carcinoma (nccRCC)
Indication:Nicht klarzelliges Nierenzellkarzinom
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
[barbara.stoehr@nct-heidelberg.de]
Investigator: Prof. Dr. Carsten Grüllich (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2016-000706-12 (siehe EU klinisches Studienregister)

Urothelial Carcinoma

BMS CA 209-274

(second-line)
Title:A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
Indication:Carcinoma, Transitional Cell
Type of study:Phase III
Contact: Ute Bickelhaupt (Kontaktperson)
[Ute.Bickelhaupt@med.uni-heidelberg.de]
Investigator: Dr. Gencay Hatiboglu (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02632409
EudraCT: 2014-003626-40 (siehe EU klinisches Studienregister)

BioClin [Rekrutierung nach Rücksprache]

Title:A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Following Platinum-based Chemotherapy.
Indication:Lokal fortgeschrittenes oder metastasiertes Urothelzellkarzinom
Type of study:Phase I
Contact: Margit Peters-Hornig (Study Nurse)
[margit.peters-hornig@med.uni-heidelberg.de]
Investigator: Prof. Dr. Carsten Grüllich (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03123055
EudraCT: 2017-001292-23 (siehe EU klinisches Studienregister)

STARTRK-2/ RXDX-101-92

Title:AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
Indication:Lokal fortgeschrittene oder metastatische solide Tumore
Type of study:Phase II
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Prof. Dr. Christoph Springfeld (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2015-003385-84 (siehe EU klinisches Studienregister)

TITAN TCC [Rekrutierung nach Rücksprache]

Title:A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma
Indication:Carcinoma Neoplasm Metastasis Carcinoma, Transitional Cell
Type of study:Phase II
Contact: Ulrike Lauterbach (Study Nurse)
[Ulrike.Lauterbach@med.uni-heidelberg.de]
Investigator: Prof. Dr. Carsten Grüllich (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03219775
EudraCT: 2016-004857-33 (siehe EU klinisches Studienregister)

Vaccibody (VBN-01) / [Rekrutierung nach Rücksprache]

Title:An open labelled first human dose phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO immunotherapy in patients with locally advanced or metastatic melanoma, NSCLC, clear renal cell carcinoma, urothelial cancer or squamous cell carcinoma of head and neck, who did not reach complete responses with current standard of care immune checkpoint blockade
Indication:Plattenepithelkarzinomen, Melanom, Kopf-/Hals Tumore, Nicht-kleinzelliger Lungenkrebs, Nierenzellkarzinom
Type of study:Phase I
Contact: Gabriele Bentz (Kontaktperson)
[gabriele.bentz@med.uni-heidelberg.de]
Investigator: Prof. Dr. Jürgen Krauss (Leiter klinische Prüfung)
Trial Register: No trial registry number given.
EudraCT: 2017-002474-39 (siehe EU klinisches Studienregister)